Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQ: SUPN · Real-Time Price · USD
46.18
-0.67 (-1.43%)
May 29, 2026, 4:00 PM EDT - Market closed
Supernus Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 776.83 | 718.95 | 661.82 | 607.52 | 667.24 | 579.78 | |
Revenue Growth (YoY) | 16.29% | 8.63% | 8.94% | -8.95% | 15.09% | 11.41% |
Cost of Revenue | 82.19 | 74.56 | 77.91 | 83.78 | 87.22 | 75.06 |
Gross Profit | 694.64 | 644.39 | 583.91 | 523.74 | 580.02 | 504.71 |
Selling, General & Admin | 520.79 | 485.56 | 321.58 | 336.36 | 377.22 | 304.76 |
Depreciation & Amortization Expenses | 95.31 | 89.46 | 77.98 | 82.39 | 82.63 | 29.99 |
Research & Development | 118.75 | 106.24 | 108.8 | 91.59 | 74.55 | 90.47 |
Other Operating Expenses | 20.15 | 25.42 | -6.11 | 18.67 | -0.51 | -6.53 |
Total Operating Expenses | 755 | 706.67 | 502.25 | 529.01 | 533.89 | 418.69 |
Operating Income | -60.36 | -62.28 | 81.67 | -5.27 | 46.12 | 86.03 |
Total Non-Operating Income (Expense) | 11.21 | 13.25 | 16.2 | 8.04 | 14.62 | -12.85 |
Pretax Income | -49.15 | -49.03 | 97.87 | 2.77 | 60.74 | 73.18 |
Provision for Income Taxes | -20.13 | -10.48 | 24.01 | 1.45 | 0.03 | 19.75 |
Net Income | -29.02 | -38.55 | 73.87 | 1.32 | 60.71 | 53.42 |
Net Income to Common | -29.02 | -38.55 | 73.87 | 1.32 | 60.71 | 53.42 |
Net Income Growth | - | - | 5512.84% | -97.83% | 13.64% | -57.92% |
Shares Outstanding (Basic) | 57 | 56 | 55 | 55 | 54 | 53 |
Shares Outstanding (Diluted) | 57 | 56 | 56 | 56 | 62 | 54 |
Shares Change (YoY) | 1.84% | 0.88% | 0.81% | -10.01% | 13.47% | 1.24% |
EPS (Basic) | -0.51 | -0.68 | 1.34 | 0.02 | 1.13 | 1.01 |
EPS (Diluted) | -0.51 | -0.68 | 1.32 | 0.02 | 1.04 | 0.98 |
EPS Growth | - | - | 6500.00% | -98.08% | 6.12% | -58.48% |
Shares Outstanding | 58.04 | 57.46 | 55.74 | 54.72 | 54.25 | 53.26 |
Free Cash Flow | 82.25 | 45.99 | 171.23 | 110.53 | 116.41 | 125.08 |
Free Cash Flow Growth | 78.82% | -73.14% | 54.91% | -5.05% | -6.93% | -7.15% |
Free Cash Flow Per Share | 1.44 | 0.81 | 3.06 | 1.99 | 1.89 | 2.30 |
Gross Margin | 89.42% | 89.63% | 88.23% | 86.21% | 86.93% | 87.05% |
Operating Margin | -7.77% | -8.66% | 12.34% | -0.87% | 6.91% | 14.84% |
Profit Margin | -3.74% | -5.36% | 11.16% | 0.22% | 9.10% | 9.21% |
FCF Margin | 10.59% | 6.40% | 25.87% | 18.19% | 17.45% | 21.57% |
EBITDA | 36.95 | 29.28 | 162.08 | 79.59 | 131.67 | 118.62 |
EBITDA Margin | 4.76% | 4.07% | 24.49% | 13.10% | 19.73% | 20.46% |
EBIT | -60.36 | -62.28 | 81.67 | -5.27 | 46.12 | 86.03 |
EBIT Margin | -7.77% | -8.66% | 12.34% | -0.87% | 6.91% | 14.84% |
Effective Tax Rate | 40.96% | 21.37% | 24.53% | 52.47% | 0.05% | 26.99% |